EXPRES2ION BIOTECHNOLOGIES APS - Denmark 

Ranking results:

Past rankings:

2020
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000

Ranking timeline:

Project Participation Performance(2020-01-01 - 2024-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 2
As coordinator: 0
As participant: 2
Sole participant: 0
Coordinator / Participant Ratio: 0*

*Ratio includes only projects with > 2 partners

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2020 0 12.704.319 771.220 2
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:Projects [No]:
ACADEMIC MEDICAL CENTRE AMSTERDAM1
ADAPTVAC APS1
CBCI SOCIETY FOR MEDICAL EDUCATION1
CELLVAX1
CHRISTIAN MEDICAL COLLEGE VELLORE1
CLINICAL DEVELOPMENT SERVICES AGENCY1
COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH1
EPIVAX INC1
GENNOVA BIOPHARMACEUTICALS LIMITED1
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE1
LEIDS UNIVERSITAIR MEDISCH CENTRUM1
LITEVAX BV1
STANIPHARM1
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM1
STICHTING RADBOUD UNIVERSITEIT1
THE UNIVERSITY OF TUEBINGEN1
TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE1
UNIVERSITAETSKLINIKUM TUEBINGEN1
UNIVERSITEIT GENT1
UNIVERSITEIT VAN AMSTERDAM1
UNIVERSITY OF COPENHAGEN1
VIROCLINICS BIOSCIENCES BV1
WAGENINGEN UNIVERSITY1

Constancy:

Total number of partners: 23
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 23
Frequent / Rare Partner Ratio: 0

Project overview:

Start dateProjectacronymrolefundingpartners
2020-04-01Prevention of SARS-CoV-2 infection through development and clinical testing of a novel Virus Like Particle (VLP) vaccine Prevent-nCoVparticipant2.728.3409
2020-04-01Effective and Affordable Flu Vaccines for the World INDIGOparticipant9.975.97916